Childhood asthma may increase risk of type 1 diabetes and IBD

Published Date: 17 Mar 2023

Denmark: COPSAC, Copenhagen Prospective Study of Childhood Asthma, researchers in Copenhagen, Denmark, noted that a higher risk...

Read Full News

Latest News

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

FDA Approves Depemokimab-ulaa (Exdensur) for Severe Asthma

FDA Approves Depemokimab-ulaa (Exdensur) for Severe Asthma

Getting Through the Door: How COPD, Lung Cancer Screening Remains Minimal

Getting Through the Door: How COPD, Lung Cancer Screening Remains Minimal

Advancing NP and PA Involvement in Pulmonary Care, CHEST Learning Susan Corbridge, PhD, Alanna Kavanugh, MSN, CCRN

Susan Corbridge, PhD, and Alanna Kavannagh, MSN, CCRN, discuss the role of advanced practice providers on the evolving pulmonary and critical care teams during CHEST 2025.

Thunderstorms Linked to Surge in Asthma ER Visits

Thunderstorms Linked to Surge in Asthma ER Visits

House Dust Mite SLIT Tablet Well Tolerated in Children With Allergic Asthma

House Dust Mite SLIT Tablet Well Tolerated in Children With Allergic Asthma

Todays Updates

Phase 3b STRENGTH Trial Provides Greater Support for Intrathecal SMA Gene Therapy Marco Meglio

Phase 3b study revealed Itvisma's safety and efficacy in treating spinal muscular atrophy, showing modest motor function improvements in patients previously on other therapies.

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

Renal Transplantation May Lower Sleep Disorder Risk Versus Dialysis

Renal Transplantation May Lower Sleep Disorder Risk Versus Dialysis

BMI, Inflammatory Bowel Disease Both Show Causal Effect on HS Development

BMI, Inflammatory Bowel Disease Both Show Causal Effect on HS Development

The HCPFive: Top News for Healthcare Providers from the Week of 12/14

The HCPFive: Top News for Healthcare Providers from the Week of 12/14

Todays Updates

Phase 3b STRENGTH Trial Provides Greater Support for Intrathecal SMA Gene Therapy Marco Meglio

Phase 3b study revealed Itvisma's safety and efficacy in treating spinal muscular atrophy, showing modest motor function improvements in patients previously on other therapies.

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

Renal Transplantation May Lower Sleep Disorder Risk Versus Dialysis

Renal Transplantation May Lower Sleep Disorder Risk Versus Dialysis

BMI, Inflammatory Bowel Disease Both Show Causal Effect on HS Development

BMI, Inflammatory Bowel Disease Both Show Causal Effect on HS Development

The HCPFive: Top News for Healthcare Providers from the Week of 12/14

The HCPFive: Top News for Healthcare Providers from the Week of 12/14

Latest News

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

FDA Approves Depemokimab-ulaa (Exdensur) for Severe Asthma

Getting Through the Door: How COPD, Lung Cancer Screening Remains Minimal

Susan Corbridge, PhD, and Alanna Kavannagh, MSN, CCRN, discuss the role of advanced practice providers on the evolving pulmonary and critical care teams during CHEST 2025.

Thunderstorms Linked to Surge in Asthma ER Visits

House Dust Mite SLIT Tablet Well Tolerated in Children With Allergic Asthma

News All Time

Nerandomilast Approval Breaks Decade-Long Dry Spell for IPF, With Toby Maher, MD, PhD Toby Maher, MD, PhD

Maher discussed the new FDA approved drug, marketed as Jascayd, and its impact for idiopathic pulmonary fibrosis.

FDA Accepts NDA for Chiesi’s Single Inhaler Triple Therapy for Asthma Victoria Johnson

The therapy is currently approved in almost 50 countries under the name Trimbow.

Mucoactives Found to Have Little Benefit for Bronchiectasis Victoria Johnson

A recent study reveals that hypertonic saline and carbocisteine do not effectively reduce pulmonary exacerbations.

4 Trials That May Change Pulmonary Embolism, with Parth Rali, MD Parth Rali, MD

Rali highlights a series of randomized, controlled trials that could reinvigorate the recently stagnant field of PE treatment development.

Sleep Apnea Significantly Impacts Mortality Benefit of GLP-1s Kevin Kunzmann

CHEST 2025 data suggest OSA is an "effect modifier" on the mortality benefit of GLP-1 receptor agonists in patients co-diagnosed with type 2 diabetes.

FDA Approval Adds Tezepelumab to CRSwNP Treatment Landscape Victoria Johnson

Tezepelumab is the first TSLP-targeting biologic to be approved for chronic rhinosinusitis with nasal poylps.

Redefining Severe Airway Disease Care: Clinicians Weigh In on Biologics and Barriers Victoria Johnson

Experts explore the evolution of asthma and COPD treatments with targeted biologic therapies.

Opportunities to Define and Treat Indoor Air Quality, with Sarath Raju, MD, MPH Sarath Raju, MD, MPH

Most clinicians are not considering poor home air exposure when treating persistent asthma or airway disease, Raju explains. That may be making a difference in outcomes.

Dupilumab, Tezepelumab Provide Consistent Real-World Severe Asthma Outcomes Kevin Kunzmann

Retrospective cohort data at CHEST 2025 show the similar efficacy profiles — but slightly different safety outcomes — among patients receiving either biologic.

The Case for More Spirometry, Pulmonary Function Testing, with Meredith McCormack, MD Kevin Kunzmann

McCormack believes simple lung function results accrued over a lifetime can optimize an individual's pulmonary care.

Clinical and Patient Definitions of Acute COPD Exacerbation Recovery Differ Greatly Kevin Kunzmann

Despite clinical definitions suggesting patients recover from exacerbations within 2 weeks of hospital discharge, most patients in a qualitative survey believed they had not achieved recovery within 3 months.

Guidelines in Review: CHEST Advises Against Routine Blood Transfusions for Critically Ill Patients During Procedures Kevin Kunzmann

Evidence-based guidelines from emphasize personalized transfusion strategies for critically ill patients, urging clinicians to avoid routine platelet and fresh frozen plasma transfusions during common procedures.

What Ails Lung Cancer Screening, with Douglas Wood, MD Douglas Wood, MD

Wood shares 3 factors that influencing our nationally poor rates of high-risk lung cancer screening.

Dry Powder Treprostinil Tolerated Among Patients with PH-ILD, with Nicholas Kolaitis, MD Kevin Kunzmann

Kolaitis discussed interim findings from the ASCENT trial, which showed ability to increase treprostinil dosing while maintaining a safe and efficacious profile.

Extended-Release Nalbuphine Improves Patient-Reported Refractory Chronic Cough Within 1 Week Imran Satia, MD, PhD

Imran Satia, MD, PhD, discusses promising phase 2A trial data showing quick and significant improvements in patients' perception of cough frequency and severity.

Baseline Type 2 Biomarkers Can Predict Asthma Remission with Dupilumab, with Mario Castro, MD, MPH Kevin Kunzmann

Castro discusses new data from CHEST 2025 showing the value of baseline blood eosinophils and FeNO in understanding potential dupilumab outcomes.

Recommended News For You

Alkem introduces cetuximab under the trade name Cetuxa in India.

Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients

Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study

Psychiatric Disorders Are Common in Dementia Patients.

Belzutifan for Advanced Renal Cell Carcinoma is approved by the FDA.

Should the UK introduce targeted prostate cancer screening? The case for and against

FDA Bans Red Dye No. 3 From Foods, Ingested Drugs

Recommended Articles For You

Unlocking the Potential of CPK Levels: How to Maximize Your Health Benefits 

Unlocking The Causes And Risk Factors Of Breast Cancer 

Hemophilia Beyond Boundaries: Unconventional Therapies in Bleeding Disorder Care 

Everything You Need To Know About Trichelemmal Cysts: Symptoms, Causes, Diagnosis And Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Antitumor cell activity in glioblastoma is controlled by blocking the triggering receptor expressed on myeloid cells 2.

2.

Momelotinib, a JAK inhibitor, has FDA approval to treat adult myelofibrosis in anemic patients.

3.

MCh in Gynecologic Oncology: Admission, Medical School, Fees, Qualifications Information

4.

Immune cell homing hydrogel-based platform captures dendritic cells to process mRNA from cancer vaccines

5.

COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment

1.

Advancements in Cancer Treatment and Survival Outcomes for Acute Myeloid Leukemia

2.

Integrative Clinical Genomics of Metastatic Cancer: Decoding Tumor Evolution for Precision Oncology

3.

Unraveling the Mysteries of Hematocrit: How It Impacts Your Health

4.

What is Hemorrhagic Cystitis and How to Manage its Symptoms

5.

Revolutionizing Cancer Treatment with Darzalex: How an Innovative Drug is Transforming Lives

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V

2.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

3.

From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD

4.

The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion

5.

Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot